Clinical trial KEYNOTE-355
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | MSD (Merck Sharp & Dohme) |
| EudraCT Identifier | 2016-001432-35 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02819518 |
| Inclusion criteria | Triple negative. Metastatic. 1s Line |
| Last update |